Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review
Wegovy and other semaglutide medications have experienced periods of limited availability, making it difficult for some patients to obtain their prescriptions.[5] During the height of the shortages, healthcare providers sometimes had to adjust dosing strategies to help patients maintain treatment.[6] Novo Nordisk, the manufacturer of Wegovy and Ozempic, has reported efforts to increase production and improve supply, though demand may still exceed availability in some areas.[7] Compounded semaglutide may be more readily available in some cases and may be less expensive for certain patients
Explore detailed drug insights and clinical data at www.clival.com #GLP1 #DiabetesCare #ObesityTreatment #PharmaInsights #DrugDatabase #ClivalDatabase To view or add a comment, sign in Indias drug regulator has officially approved Ozempic (semaglutide injection) by Novo Nordisk for the treatment of Type 2 Diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] 9.Tang G., Gudsnuk K., Kuo S.-H., Cotrina M.L., Rosoklija G., Sosunov A., Sonders M.S., Kanter E., Castagna C., Yamamoto A., et al
(2011) 13:e11
References Lau J, et al